Article thumbnail

Systemic BCG Immunization Induces Persistent Lung Mucosal Multifunctional CD4 TEM Cells which Expand Following Virulent Mycobacterial Challenge

By Daryan A. Kaveh, Véronique S. Bachy, R. Glyn Hewinson and Philip J. Hogarth


To more closely understand the mechanisms of how BCG vaccination confers immunity would help to rationally design improved tuberculosis vaccines that are urgently required. Given the established central role of CD4 T cells in BCG induced immunity, we sought to characterise the generation of memory CD4 T cell responses to BCG vaccination and M. bovis infection in a murine challenge model. We demonstrate that a single systemic BCG vaccination induces distinct systemic and mucosal populations of T effector memory (TEM) cells in vaccinated mice. These CD4+CD44hiCD62LloCD27− T cells concomitantly produce IFN-γ and TNF-α, or IFN-γ, IL-2 and TNF-α and have a higher cytokine median fluorescence intensity MFI or ‘quality of response’ than single cytokine producing cells. These cells are maintained for long periods (>16 months) in BCG protected mice, maintaining a vaccine–specific functionality. Following virulent mycobacterial challenge, these cells underwent significant expansion in the lungs and are, therefore, strongly associated with protection against M. bovis challenge. Our data demonstrate that a persistent mucosal population of TEM cells can be induced by parenteral immunization, a feature only previously associated with mucosal immunization routes; and that these multifunctional TEM cells are strongly associated with protection. We propose that these cells mediate protective immunity, and that vaccines designed to increase the number of relevant antigen-specific TEM in the lung may represent a new generation of TB vaccines

Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2003). A DNA prime-live vaccine boost strategy in mice can augment IFN-gamma responses to mycobacterial antigens but does not increase the protective efficacy of two attenuated strains of Mycobacterium bovis against bovine tuberculosis.
  2. (2011). A multistage tuberculosis vaccine that confers efficient protection before and after exposure.
  3. (1977). A selective oleic acid albumin agar medium for the cultivation of Mycobacterium bovis.
  4. (1986). Aerogenic vaccination of mice with Mycobacterium bovis BCG.
  5. (2006). An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis.
  6. (2011). Borrebaeck CA (2004) CD272 CD4+ memory T cells define a differentiated memory Systemic BCG Induces Persistent Lung CD4
  7. (2007). CD27low CD4 T lymphocytes that accumulate in the mouse lungs during mycobacterial infection differentiate from CD27high precursors in situ, produce IFN-gamma, and protect the host against tuberculosis infection.
  8. (2004). CD4 T cells producing IFN-gamma in the lungs of mice challenged with mycobacteria express a CD27-negative phenotype.
  9. (1998). CD49d expression and function on allergen-stimulated T cells from blood and airway.
  10. (2009). Cell-mediated immune responses in tuberculosis.
  11. (2002). Correlation of ESAT-6-specific gamma interferon production with pathology in cattle following Mycobacterium bovis BCG vaccination against experimental bovine tuberculosis.
  12. (2008). Development of a Mycobacterium bovis intranasal challenge model in mice.
  13. (2006). Development of vaccines against bovine tuberculosis.
  14. (2010). Different routes of bacterial infection induce long-lived TH1 memory cells and short-lived TH17 cells.
  15. (2009). Early pulmonary cytokine and chemokine responses in mice immunized with three different vaccines against Mycobacterium tuberculosis determined by PCR array.
  16. (2006). Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness.
  17. (2001). Epidemiology of selected mycobacteria that infect humans and other animals.
  18. (2010). Expanded polyfunctional T cell response to mycobacterial antigens in TB disease and contraction posttreatment.
  19. (2001). Failure to induce enhanced protection against tuberculosis by increasing T-cell-dependent interferon-gamma generation.
  20. (2005). Frequency of IFN-gamma producing cells correlates with adjuvant enhancement of bacille Calmette-Guerin induced protection against Mycobacterium bovis.
  21. (2005). Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence.
  22. (2007). Half-truths and selective memory: Interferon gamma, CD4(+) T cells and protective memory against tuberculosis.
  23. (2006). High frequency of CD4+ T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection.
  24. (2010). Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant.
  25. (2005). Hill A
  26. (2006). HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells.
  27. (2007). Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations.
  28. (2009). Immunity to respiratory viruses.
  29. (2003). In situ study of abundant expression of proinflammatory chemokines and cytokines in pulmonary granulomas that develop in cynomolgus macaques experimentally infected with Mycobacterium tuberculosis.
  30. (2003). Lymphocyte homing to bronchus-associated lymphoid tissue (BALT) is mediated by Lselectin/PNAd, alpha4beta1 integrin/VCAM-1, and LFA-1 adhesion pathways.
  31. (2005). Mechanisms of mucosal and parenteral tuberculosis vaccinations: adenoviralbased mucosal immunization preferentially elicits sustained accumulation of immune protective CD4 and CD8 T cells within the airway lumen.
  32. (2010). Multifunctional CD4(+) T cells correlate with active Mycobacterium tuberculosis infection.
  33. (2007). Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major.
  34. (2008). Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice.
  35. (2006). Oral delivery of lipid-encapsulated Mycobacterium bovis BCG extends survival of the bacillus in vivo and induces a long-term protective immune response against tuberculosis.
  36. (2009). Pattern and diversity of cytokine production differentiates between Mycobacterium tuberculosis infection and disease.
  37. (2008). Peripheral blood gamma interferon release assays predict lung responses and Mycobacterium tuberculosis disease outcome in mice.
  38. (2010). Phenotypic definition of effector and memory T-lymphocyte subsets in mice chronically infected with Mycobacterium tuberculosis.
  39. (2007). Poor correlation between BCG vaccination-induced T cell responses and protection against tuberculosis.
  40. (2005). PPD induced in vitro interferon gamma production is not a reliable correlate of protection against Mycobacterium tuberculosis.
  41. (2008). rBCG induces strong antigen-specific T cell responses in rhesus macaques in a prime-boost setting with an adenovirus 35 tuberculosis vaccine vector.
  42. (2010). Respiratory mucosal immunization with adenovirus gene transfer vector induces helper CD4 T cell-independent protective immunity.
  43. (2009). Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals.
  44. (2004). Single intranasal mucosal Mycobacterium bovis BCG vaccination confers improved protection compared to subcutaneous vaccination against pulmonary tuberculosis.
  45. (2006). STAT1 in peripheral tissue differentially regulates homing of antigen-specific Th1 and Th2 cells.
  46. (2005). Stepwise differentiation of CD4 memory T cells defined by expression of CCR7 and CD27.
  47. (2008). T-cell quality in memory and protection: implications for vaccine design.
  48. (2010). The {alpha}4{beta}1 Integrin in Localization of Mycobacterium Tuberculosis-specific Th1 Cells to the Human Lung.
  49. (2010). The Achilles heel of BCG.
  50. (1994). The BCG experience: Implications for future vaccines against tuberculosis.
  51. (1992). The CD27- subset of peripheral blood memory CD4+ lymphocytes contains functionally differentiated T lymphocytes that develop by persistent antigenic stimulation in vivo.
  52. (2004). The influence of remaining live BCG organisms in vaccinated mice on the maintenance of immunity to tuberculosis.
  53. (2006). The LFA-1 adhesion molecule is required for protective immunity during pulmonary Mycobacterium tuberculosis infection.
  54. (2010). The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults.
  55. (2009). Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells.